Atlanta, Georgia, and London, UK 27 May 2014: A State of Georgia initiative making it possible to treat children with epilepsy with cannabidiol is moving forward. The state, GW Pharmaceuticals (NASDAQ: GWPH), and Georgia Regents University Augusta (GRU), announced today that they have entered into a Memorandum of Understanding to study GW's investigational cannabidiol (CBD) product Epidiolex® in the treatment of children with medication-resistant epilepsies.
Georgia Governor Nathan Deal announced in April his support for clinical research that would investigate the use of CBD, a non-psychoactive component of the cannabis plant, and develop rigorous data that will inform and expand the scientific community's understanding of potential treatments for difficult-to-treat forms of childhood epilepsies. Deal's commitment to this research has led to this plan to form collaboration between GRU and GW Pharmaceuticals. It is expected that details of the collaboration will be finalized in the coming months in order for research to commence later this year.
News 
Market Data 
Discover 
